trans-7,8-diol; CPA, cyclophosphamide; Cr(III), trivalent chromium; Cr(VI), hexavalent chromium; CSC, cigarette smoke condensate; DMSO, dimethylsulfoxide; DPC, s-diphenylcarbazide; ELF, epithelial-lining fluid;
G6PD, glucose-6-phosphate dehydrogenase; ICR191, 2-methoxy-6-chloro-9[342-chloroethyl)aminopropylamino]acridine * 2HCI; 4NQO, 4- nitroquinoline-N-oxide; PAM, pulmonary alveolar macrophage; PCB, polychlorinated biphenyl; pCMB, p-chloromercuribenzoate; 6PGD, phosphogluconate dehydrogenase.
In spite of its classification as a human carcinogen, there are several defense mechanisms in the organism, based on chemical or biochemical oxido-reductive processes, which tend to limit the possible target ofchromium carcinogenicity and to constitute a threshold to its activity (3, (5) (6) (7) (8) . For instance, Cr(VI) is reduced in human plasma (9) and inside erythrocytes (10, 1 1), this being in agreement with the finding that chromium typically produces tumors at implant sites (1) . Saliva and especially gastric juice are also quite effective in reducing Cr(VI) ( 12) , thus constituting a hardly surmountable barrier to the metal introduced by the oral route or swallowed after reflux from the respiratory tract. In fact, Cr(III) is not capable of permeating mammalian cell membranes (3, 5) and is very poorly absorbed by the intestine (13) .
Additionally, Cr(VI) is reduced by whole cell homogenates and subcellular fractions from a variety of tissues in different animal species (6, 11, 12, 14) . The underlying biochemical mechanisms have been elucidated, at least in part, and ascribed to various reductive reactions occurring in mitochondria (15), in microsomes (7, 16, 17) , and in the cytosol, where reduction can be promoted by electron donors, such as reduced glutathione, and chiefly by NADH-and NADPH-dependent enzyme-catalyzed mechanisms, among which the DT-diaphorase activity (7) .
Interestingly, these mechanisms can also be detected in lung cell preparations (7) , where they appear to be stimulated not only by enzyme inducers but also by the repeated intratracheal administration of Cr(VI) itself to rats (6) . Reduction of Cr(VI) has been obtained in the presence ofvarious rat lung preparations (6, 7) , and a decrease of its mutagenicity has been also shown to occur in the presence of a large number of samples of mixedcell populations prepared from human lung peripheral parenchyma or from bronchial tree (18) .
We have now investigated whether Cr(VI) can be also reduced, before getting in contact with the target tissue, by the extracellular environment of the lower respiratory tract-the so-called epithelial-lining fluid (ELF)-and by pulmonary alveolar macrophages (PAM). These cells are well known to play an important role as defense mechanisms ofthe respiratory tract against inhaled foreign material ( 19) and have been demonstrated to interact with chromium also. In fact, this and other metals could be detected by x-ray analysis in cells of welders (20) . Furthermore, particles coated with chromium were phagocytized at a faster rate by rabbit PAM (21), the intratracheal administration of chromates to rats resulted in an increase frequency of PAM foci (22), and their inhalation stimulated PAM phagocytic activity (23).
Aroclor 1254, a polychlorinated biphenyl (PCB) stimulating a wide spectrum of enzyme activities and behaving as the most potent inducer of chromium metabolism in rat liver and lung cells (6) , was evaluated in rat PAM.
Methods
Patients. Alveolar macrophages were obtained from 47 patients undergoing bronchoalveolar lavage for evaluation of localized, noninflammatory lung lesions. They were classified according to age, sex, disease, and smoking habits.
Animals. 40 male, adult Sprague-Dawley rats ("Morini" strain), weighing -300 g, were used. The animals were divided into two groups and, 5 d before killing, they were treated with a single intraperitoneal injection of 200 ul ofeither corn oil (controls) or of Aroclor 1254 (Monsanto Corp., St. Louis, MO) (500 mg/kg body wt) diluted in corn oil.
Procedure ofbronchoalveolar lavage (BAL). BAL was performed as previously described (24) . Briefly, the trachea and upper airways of patients were anesthetized with xylocaine spray and a fiberoptic bronchoscope, having a 5-mm tip, was introduced through the nose and wedged in a third-or fourth-order bronchus. One or two segments were lavaged in each patient by infusing sterile isotonic saline in five 20-ml aliquots, with a typical return of 40-60 ml per each 100 ml infused. In all cases, only dose portions of the lung free of disease, as evaluated by chest xray analysis and by bronchoscopic examination, were lavaged. The fluid was collected in plastic sterile containers in order to minimize adhesion of macrophages and kept at 4°C. A small portion was used for cell count and for cell viability evaluation by trypan blue exclusion.
The remaining fluid was spun at 500 g for 5 min in a refrigerated centrifuge. The cell-free supernatant, containing diluted ELF, was collected and, for 15 patients, it was kept at -80°C.
The cell pellet was washed twice with a 50 mM Tris-0.25 M sucrose solution, pH 7.4, and in the meantime a differential count was made by using a Giemsa-stained cytocentrifuge preparation (Cytospin). Samples containing <90% macrophages were not used for this study. The other samples were resuspended at a concentration of 5 X 106 PAM/ml of Tris-sucrose and frozen at -80°C. The number of macrophages obtained from each patient varied, especially depending on smoking habits, from 4 to 25 X 106 for every segment lavaged.
Recovery of PAM was obtained in rats subjected to general anesthesia with ether. The lungs were perfused with heparinized 0.15 M NaCl and subsequently lavaged with five 10-ml aliquots of sterile 0.15 M NaCl, infused via a cannula inserted in trachea. Preparation of the PAM suspension was carried out as described for humans, with a mean recovery of -0.8 X 106 PAM per animal. Due to this low recovery, all the samples collected within each one of the two groups of 20 rats were pooled together.
Preparation ofPAM homogenates and subfractions. All steps were carried out at 00-40C, using sterile materials and operating under aseptic conditions. PAM suspensions were thawed and homogenized by means ofa Polytron blender. When needed, homogenates were further processed by differential centrifugation, e.g., for 15 min at 2,000, 9,000, and 20,000 g, using a MLW K24 refrigerated centrifuge, and for 60 min at 105,000 g using a Beckman Spinco L2-65B ultracentrifuge. Homogenates Evaluation of Cr(VI) reduction. For evaluating Cr(VI) reduction, varying amounts of sodium dichromate were mixed with PAM homogenates or subfractions, or with S-9 fractions of other tissues, and either combined with NADPH or NADH or incorporated into S-9 mix (representing 50-75% of the reaction mixture). S-9 mix is a NADPH-generating system composed of 8 mM MgCl2, 33 mM KCI, 5 mM G6P, 4 mM NADP+, and 100 mM sodium phosphate, pH 7.4. In some experiments, metabolic inhibitors (dicumarol, pCMB, L-thyroxine) or oxidizing agents (potassium permanganate) were also added. The final volume of all these mixtures (0.5 ml) was obtained by adding 0.2 M phosphatebuffered saline, pH 7.4, unless otherwise specified.
After varying time intervals of mixing in a rotary shaker (10 rpm) at 37°C, the tubes were transferred into an ice-cold bath. Each mixture was then divided into two cuvettes, one ofthem (sample) filled with 2.25 ml of DPC reagent (40 mg of DPC in 100 ml of 19% ethanol and 8% sulfuric acid in water) and the other one (blank) filled with 2.25 ml of the same acid-ethanol mixture, but without DPC. After 10 to 15 min at room temperature, the resulting chromium-diphenylcarbazonium complex was measured at 540 nm in a Beckman DU7 spectrophotometer. Detailed calibration curves were drawn by testing standard solutions of untreated sodium dichromate.
Biochemical analyses. The protein concentration in ELF and in cell or tissue preparations was determined according to the protein-dye method of Bradford (25) .
The enzyme activities measured in PAM included: G6PD (EC 1.1.1.49) and 6PGD (EC 1.1.1.43) (both assayed according to Rudack et al. [261) . Diaphorase activities with either NADPH or NADH as electron donors were assayed with 2,4-dichlorophenolindolphenol as electron acceptor, as described by Ernster et al. (27) . All The choice ofthe Salmonella strain and ofthe optimal concentration of each compound (in 100 Ml DMSO or distilled water)-which are reported in Results (see Table V )-was decided on the basis of earlier experiments with the same compounds (29) and on the results of preliminary assays. The complete metabolic system was composed of PAM S-9 fractions incorporated in a NADPH-generating system (S-9 mix), having a standard composition (28) and used at 0.5 ml/plate. Liver S-9 fractions from Aroclor-treated Sprague-Dawley rats were also tested in order to check the efficiency of the system.
The spontaneous mutation rate ofeach bacterial strain (strain controls in Table V PAM homogenates (Table I) . Heating of the complete metabolic system also resulted in the elimination ofthe bulk ofthe reaction. Similar results were obtained in the presence either ofequimolar NADH or of NADPH, or of the NADPH-generating system (S-9 mix).
Time dependence ofCr(VI) reduction by PAM homogenates.
The reaction was characterized by a rapid onset, followed by a substantially decreased rate after the first 30 min (Fig. 2) .
Substrate dependence of Cr(VI) reduction by PAM homogenates. As shown in Fig. 3 , the efficiency of Cr(VI) reduction by PAM homogenates was linearly related to availability of sodium dichromate, until attaining a plateau. At the highest con- of PAM or tissue S-9 fractions. To this purpose, samples of human S-i12 or rat S-9 fractions were accurately normalized in their protein content and then comparatively assayed for their Cr(VI)-reducing ability in the presence of S-9 mix co-factors.
The results shown in Table IV demonstrate that BSA was ineffective in reducing Cr(VI), whereas PAM S-9 fractions were the most effective, with significant differences as compared with S-12 fractions prepared from a mixed cell population either of human bronchial tree or of lung peripheral parenchyma, or of S-9 fractions of rat lung or liver. In this comparison it should be noted that bronchial tree and lung peripheral parenchyma samples were obtained from the same surgery patients, whereas PAM were obtained from other individuals. The same rank of activity was confirmed in two additional experiments. Reduction of Cr(VI) after incubation for 4 h at 37°C of sodium dichromate [28.6 Mg, containing 10 gg Cr(VI)] with S-9 mix (75%, vol/ vol) containing either BSA or S-9 (or S-12) fractions from human or rat cell homogenates (each of them pooled from five individuals or animals). Values are means±SE of triplicate determinations (see the text). * Significantly lower as compared with values of human PAM (P Effect of PAM S-9 fractions on the mutagenicity of Cr(VI) and of other compounds. The ability of PAM S-9 fractions in reducing Cr(VI) was confirmed in the Ames reversion test. In fact, the mutagenicity of dichromate to both strains TA 100 and TA 102 of S. typhimurium was markedly decreased in the presence of these PAM preparations, as shown in Table V and as confirmed in several separate experiments. Obviously, although demonstrating the same trend, the data obtained in this biological test system and those resulting from colorimetric analyses cannot be compared from a quantitative point of view. This is also true because, in the mutagenicity test system, Cr(VI) and PAM preparations were preincubated for 60 min before plating with bacteria, but some additional metabolic reduction might have occuffed in the soft agar overlay, depending on the rapidity of Cr(VI) in penetrating into cells. Table V also shows the ability of PAM S-9 fractions to decrease the activity of two direct-acting mutagens (4NQO and ICR 191) and in activating five procarcinogens [B(a)P, B(a)P-7,8-diol, 2AF, CSC, and CPA]. Liver S-9 fractions from Aroclortreated rats were also assayed in order to check the efficiency of the system. PAM preparations, at the maximum concentration tested (corresponding to 1 X I05 cells/plate), failed to convert procarcinogens into mutagenic metabolites. In contrast, a significant decrease in mutagenic activity, although less pronounced than in the case of Cr(VI), was produced by PAM S-9 fractions on the antitumor compound ICR19 1.
Discussion
The results obtained in this study provide first evidence that the epithelial-lining fluid recovered from the extracellular environment of terminal airways has a detectable activity in reducing Cr(VI). In addition, as shown both by colorimetric analyses and in the mutagenicity test system, reduction of chromium was particularly efficient in PAM homogenates and in their subcellular fractions. In fact, at equivalent protein concentration the specific reducing activity of human PAM was by far higher than that displayed by ELF. Moreover, it significantly exceeded the reducing capacity of mixed-cell populations from human lung peripheral parenchyma or bronchial tree, or from rat lung or liver cells. All these preparations are capable of reducing, to a variable extent, the mutagenicity of Cr(VI) (6, 18) .
Reduction of chromium by PAM was afforded by various subcellular fractions, but mainly by cytosolic components. Most of this activity was thermolabile and required the supply of exogenous NADH or NADPH, either as such or produced by a NADPH-generating system (S-9 mix). These patterns demonstrate the involvement of enzyme-catalyzed mechanisms in the intracellular chromium reduction, as further supported by the finding that the efficiency of the reaction was directly related to the amount of the substrate [Cr(VI)] until reaching a plateau, indicating a saturation phenomenon.
The reaction was better achieved in a slightly acidic environment and was counteracted not only by the oxidizing agent permanganate but also by some metabolic inhibitors, the most efficient ofwhich was the sulphydryl group reagent pCMB. Some inhibition was also obtained with L-thyroxine and dicumarol, a specific inhibitor of DT-diaphorase (27) , suggesting that this enzyme activity, which had been so far demonstrated to afford detoxification of some organic compounds (27, 31, 32) , can also give a partial contribution to reduction of Cr(VI) in human PAM.
Due to the inability of Cr(III) to permeate mammalian cell membranes (3, 5) , reduction of Cr(VI) by ELF appears to represent a first defensive barrier against inhaled chromium, based on oxido-reductive mechanisms. A further, more important barrier is likely to be represented by the enzyme-catalyzed reduction of Cr(VI) in the cytoplasm of PAM, the multiplication and phagocytosis ofwhich is stimulated by chromium itself(21-23). As extensively discussed (6) , irrespective of the valence of chromium bound to DNA, the species resulting from Cr(VI) reduction in the cytoplasm [Cr(III) and Cr(V)] are expected to be trapped outside the cell nucleus. In addition to this detoxification process, phagocytosis by PAM should lead to sequestration of Cr(VI) in a virtually irreversible way, due to the extremely long life span of these cells (months to years) (33) and to their very efficient removal by the muco-ciliatory escalator, accounting for one-to five-million cells per hour leaving the lung and being either expectorated or swallowed (34) . These findings give further support to the view that the pulmonary carcinogenesis by chromium is subjected to threshold phenomena. In fact, it is evident that inhaled Cr(VI) must exceed not only the aspecific defense mechanisms of the respiratory tract, but also the reducing ability of ELF and the specific metabolic pathways reducing chromium in the cytoplasm of both sweeping cells (PAM) and of target cells. Such a conclusion is in agreement with the results of an extensive intratracheal carcinogenicity study performed with sodium dichromate and calcium chromate in solution, which showed a weak carcinogenic effect only in the respiratory tract, at the highest doses tested and in animals treated with single, weekly doses rather than in fractionated, daily doses (22). These patterns-i.e., carcinogenicity only at the implant site, at the highest dose, without doseresponse effects, and following massive administrations rather than repeated, fractionated administrations-meet the criteria suggested for ascribing a threshold character to the carcinogenic response (8) and are supported by the underlying detoxification mechanisms.
Experiments aiming at assessing the inducibility of Cr(VI) reduction by PAM preparations showed that the PCB Aroclor 1254, which is a potent and wide-spectrum inducer of both microsomal (35) and cytosolic (7) enzymes, stimulated in rats a slight yet significant increase in activity.
Irrespective ofthe clinical diagnosis, smoking habits had significant effects on the Cr(VI)-reducing activity of alveolar macrophages and on the biochemical parameters monitored. Cigarette smoke is known to elicit a variety of effects on PAM, including a considerable increase in the number of cells, an enlargement in their mean diameter, formation of cytoplasmic inclusions containing pigmented residues of the smoke, as well as a wide range of biochemical alterations (19, 36) . In PAM preparations of smokers, especially if smoking shortly before bronchoalveolar lavage, we found an increased ability to reduce Cr(VI) and a stimulation of enzyme activities, such as G6PD and 6PGD, and NADPH-and NADH-dependent diaphorases.
In any case, with the exception of NADPH-dependent diaphorase (the specific activity of which was found to be stimulated by recent smoke), all the differences observed between nonsmokers, exsmokers, and smokers were settled when comparisons were made in terms of specific activity, i.e. at equivalent protein concentration. Accordingly, the enhanced activities measured at equivalent number of cells can be ascribed to the increased amounts of protein consequent to cigarette smoking rather than to specific metabolic inductions. Nevertheless, for practical purposes it is important that the increase both in the number ofmacrophages (which also in this study was confirmed by a considerably higher recovery of cells by bronchoalveolar lavage) and in their protein content are expected to result in a magnified phagocytosis and reduction of Cr(VI) in PAM of smokers.
This study gives further support to the view that alveolar macrophages can play some role in metabolizing chemical carcinogens, either in the sense of activation or of deactivation.
These cells contain low yet detectable amounts of cytochromes P-450 (37, 38) and their aryl hydrocarbon hydroxylase activity appears to be inducible in situ by cigarette smoke (39, 40) . Typical procarcinogens or their proximate metabolites, such as B(a)P and B(a)P-7,8-diol, were found to induce an increase in the number of mutants after co-incubation of cultured human (41) or rabbit (42) PAM with V-79 cells. These polycyclic aromatic hydrocarbons and other procarcinogens failed to elicit any mutagenic response in our experimental system, involving co-incubation ofa suitable S. typhimurium strain with PAM S-9 fractions. A negative result was also reported in another laboratory, by testing 2AAF in a chamber mutagenicity assay using rabbit PAM as metabolizing system and S. typhimurium as genetic target (38) . It should be mentioned that the amount of cells that we could use for the preparation of PAM S-9 fractions was quite low, as compared with the rodent liver S-9 fractions, which are generally used in the Ames reversion test and are obtained from 25% (wt/vol) homogenates. Nevertheless, these preparations were capable of reducing the mutagenicity of sodium dichromate and, to a lower yet significant extent, that of ICR 191 antitumor compound. Another study showed that incubation with cultured rabbit PAM of diesel particles containing nitroaromatics, such as 1-nitropyrene, results in a considerable loss of mutagenicity for S. typhimurium (43).
Thus, on the whole, it is apparent that alveolar macrophages not only represent an important aspecific defense mechanism by engulfing and sequestering particulates carrying mutagenic/ carcinogenic agents-but in some cases they also possess metabolic systems competent to achieve the intracellular detoxification of direct-acting chemicals.
